Story
Krystal Biotech Stock Slides After VYJUVEK Revenue Misses Estimates
Krystal Biotech (NASDAQ: KRYS) shares declined significantly on Monday after the company reported second-quarter financial results that missed Wall Street's revenue expectations, overshadowing otherwise solid operational performance.
Top-Line Miss Triggers Sell-Off
The biotechnology firm announced global net revenue of $119.2 million for its flagship product, VYJUVEK, in the second quarter of 2026. According to the company's pre-market earnings release, this figure represented a 24% increase compared to the same period last year but fell short of the analyst consensus forecast of approximately $126 million.
Investor reaction was swift, with the stock falling 6.2% in pre-open trading. The shares opened at $364.66 before retreating sharply, reflecting investor disappointment with the top-line figure.
Context and Market Reaction
The sell-off appears to be a classic case of "sell the news" profit-taking. Krystal Biotech's stock had experienced a strong run-up heading into the earnings announcement, trading near its 52-week high of $382.54. This elevated the market's expectations, making the stock vulnerable to any perceived weakness in the report.
AdThe decline was company-specific, as the broader market provided little headwind; both the S&P 500 and Nasdaq Composite were modestly positive during the session. While analysts are reportedly still constructive on the company's long-term prospects, no immediate ratings upgrades emerged to counter the selling pressure.
Underlying Metrics Remain Strong
Despite the revenue shortfall, Krystal Biotech's report highlighted several positive operational metrics that were overshadowed by the headline miss. Key underlying strengths included:
- Gross margins holding firm at a robust 95%.
- The prescriber base for VYJUVEK expanding to over 640 unique prescribers.
These figures suggest a healthy commercial trajectory for the drug, but investors on Monday focused primarily on the failure to meet near-term revenue expectations.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.